The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patientsMyeloma, News25 July 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
MPE member spotlight: Fundacja Carita´s European Forum of Haemato-Oncological PatientsMPE, News6 February 2025
Register for MPE´s European Young Myeloma Patients Group webinar on myeloma and physical fitnessMPE, Myeloma, News5 February 2025
The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patientsAccess, Myeloma, News24 January 2025
MPE webinar on ASH 2024 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, Myeloma, News29 November 2024
MPE provided feedback on the HTA Implementing Regulation on joint scientific consultations on medical devices and in vitro diagnostic medical devices at Union levelMPE, News27 November 2024
